Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease.
Yujiro NakanoMasanori MurakamiKazunari HaraTatsuya FukudaMasato HorinoAkira TakeuchiYoshihiro NiitsuKumiko ShibaKazutaka TsujimotoChikara KomiyaMinato YokoyamaKenji IkedaTakanobu YoshimotoYasuhisa FujiiTetsuya YamadaPublished in: Clinical endocrinology (2022)
Our study suggests that treatment of PA in stage 3 CKD is safe and useful in preventing renal injury.
Keyphrases